Skip to main content

Advertisement

SpringerLink
Log in

Nausea and Vomiting: a Palliative Care Imperative

  • Palliative Medicine (A Jatoi, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

This review was undertaken to survey recent literature for research reports and comprehensive clinical reviews addressing the pharmacologic management of nausea and vomiting (N&V) in advanced cancer. The goal was to integrate findings in a comprehensive article that incorporates palliative care concepts into antiemetic treatment.

Recent Findings

There are few published studies of N&V in advanced cancer; such research may be limited by the multicausal nature of N&V and participant burden to patients with life-limiting disease. Most articles are written by oncologists who also specialize in palliative care, and those addressing adverse effects of drugs used as antiemetics are found in other literature. Articles addressing more novel therapies, like cannabinoids and medical marijuana, are uncommon in the oncology literature.

Summary

N&V in patients with progressive or advanced cancer is often multicausal. Nausea is more common and persistent, and even mild nausea is bothersome and may cause anxiety or depression. The mechanisms of nausea and vomiting overlap, but different neural pathways constitute the final pathway for each—the brainstem for vomiting and higher brain regions for nausea. Common causes of N&V in advanced cancer include constipation, opioids, and malignant bowel obstruction. About 40% have undetermined causes and may be exacerbated by impaired gastric emptying, chemical imbalances, or other factors. Several drugs that have antiemetic effects and act at different receptors are used to palliate N&V. There is a paucity of research that supports palliative antiemetic choices, and other research is needed to define potential therapeutic strategies that capitalize on differences between nausea and vomiting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Hawley PH. The bow tie model of 21st century palliative care. J Pain Symptom Manag. 2014;47(1):e2–5. https://doi.org/10.1016/j.jpainsymman.2013.10.009.

    Article  Google Scholar 

  2. Li B, Mah K, Swami N, et al. Symptom assessment in patients with advanced cancer: are the most severe symptoms the most bothersome? J Palliat Med. 2019. https://doi.org/10.1089/jpm.2018.0622.

    Article  Google Scholar 

  3. • Napadow V, Sheehan JD, Kim J, et al. The brain circuitry underlying the temporal evolution of nausea in humans. Cereb Cortex. 2013;23:806–13. https://doi.org/10.1093/cercor/bhs073. Functional MRI study investigated brain regions involved in temporal evolution of nausea; greater nausea intensity was associated sustained activation in a broader network of interoceptive, limbic, somatosensory, and cognitive processing areas in the human brain.

    Article  PubMed  Google Scholar 

  4. Balaban CD, Yates BJ. What is nausea? A historical analysis of changing views. Auton Neurosci. 2017;202:5–17. https://doi.org/10.1016/j.autneu.2016.07.003.

    Article  PubMed  Google Scholar 

  5. •• Wickham RJ. Revisiting the physiology of nausea and vomiting—challenging the paradigm. Support Care Cancer. Online first: 06 August 2019. https://doi.org/10.1007/s00520. Current, in-depth review of differing physiological mechanisms, neural pathways, transmitters and receptors for vomiting and for nausea; new proposed paradigm for nausea and for vomiting.

  6. Gogolla N. The insular cortex. Curr Biol. 2017;27:R573–91. https://doi.org/10.1016/j.cub.2017.05.010.

    Article  CAS  Google Scholar 

  7. Craig AD. How do you feel — now? The anterior insula and human awareness. Nat Rev Neurosci. 2009;10:59–70. https://doi.org/10.1038/nrn2555.

    Article  CAS  PubMed  Google Scholar 

  8. Harder S, Herrstedt J, Isaksen J, et al. The nature of nausea: prevalence, etiology, and treatment in patients with advanced cancer not receiving antineoplastic treatment. Support Care Cancer. 2019. https://doi.org/10.1007/s00520-018-4623-1.

    Article  Google Scholar 

  9. Singh P, Yoon SS, Kuo B. Nausea: a review of pathophysiology and therapeutics. Ther Adv Gastroenterol. 2016;9(1):98–112. https://doi.org/10.1177/1756283X15618131.

    Article  CAS  Google Scholar 

  10. Sande TA, Laird BJ, Fallon MT. The management of opioid-induced nausea and vomiting in patients with cancer: a systematic review. J Palliat Med. 2019;22(1):90–7. https://doi.org/10.1089/jpm.2018.0260.

    Article  PubMed  Google Scholar 

  11. Glare P, Miller J, Nikolova T, Tickoo R. Treating nausea and vomiting in palliative care: a review. Clin Interv Aging. 2011;6:243–59. https://doi.org/10.2147/CIA.S13109.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Walsh D, Davis M, Ripamonti C, Bruera E, Davies A, Molassiotis A. 2016 updated MASCC/ESMO consensus recommendations: management of nausea and vomiting in advanced cancer. Support Care Cancer. 2017;25:333–40. https://doi.org/10.1007/s00520-016-3371-3.

    Article  PubMed  Google Scholar 

  13. Collis E, Mather H. Nausea and vomiting in palliative care. BMJ. 2015;351:h6249. https://doi.org/10.1136/bmj.h6249.

    Article  CAS  PubMed  Google Scholar 

  14. Ferguson HJM, Ferguson CI, Speakman J, Ismail T. Management of intestinal obstruction in advanced malignancy. Ann Med Surg (Lond). 2015;4(3):264–70. https://doi.org/10.1016/j.amsu.2015.07.018.

    Article  Google Scholar 

  15. • Laval G, Marcelin-Benazech B, Guirimand F, et al. Recommendations for bowel obstruction with peritoneal carcinomatosis. J Pain Symptom Manag. 2014;8(1):75–91. https://doi.org/10.1016/j.jpainsymman.2013.08.022. French Health Authority (HAS) evidence-based clinical guidelines for the diagnosis and management of bowel obstruction.

    Article  Google Scholar 

  16. Soriano A, Davis MP. Malignant bowel obstruction: individualized treatment near the end of life. Cleve Clin J Med. 2011;78(3):197–206. https://doi.org/10.3949/ccjm.78a.10052.

    Article  PubMed  Google Scholar 

  17. Obita GP, Boland EG, Currow DC, Johnson MJ, Boland JW. Somatostatin analogues compared with placebo and other pharmacologic agents in the management of symptoms of inoperable malignant bowel obstruction: a systematic review. J Pain Symptom Manag. 2016;52(6):901–19. https://doi.org/10.1016/j.jpainsymman.2016.05.032.

    Article  Google Scholar 

  18. Peng X, Wang P, Li S, Zhang G, Hu S. Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer. World J Surg Oncol. 2015;13:50. https://doi.org/10.1186/s12957-015-0455-3.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Harris DG. Nausea and vomiting in advanced cancer. Br Med Bull. 2010;96(1):175–85. https://doi.org/10.1093/bmb/ldq031.

    Article  PubMed  Google Scholar 

  20. To THM, Agar M, Yates P, Currow DC. Prescribing for nausea in palliative care: a cross-sectional national survey of Australian palliative medicine doctors. J Palliat Med. 2014;17(9):1032–6. https://doi.org/10.1089/jpm.2013.0610.

    Article  Google Scholar 

  21. Valkova M, Stamenov B, Peychinska D, et al. Metoclopramide-induced extrapyramidal signs and symptoms – brief review of literature and case report. J IMAB. 2014;20(6):539–41. https://doi.org/10.5272/jimab.2014206.539.

    Article  Google Scholar 

  22. Gordon P, LeGrand SB, Walsh D. Nausea and vomiting in advanced cancer. Eur J Pharmacol. 2014;722:187–91. https://doi.org/10.1016/j.ejphar.2013.10.010.

    Article  CAS  PubMed  Google Scholar 

  23. Gupta N, Puri S, Kumar V, Garg R, Bharati SJ, Mishra S, et al. Olanzapine in the treatment of refractory nausea and vomiting in palliative care settings. Indian J Palliat Care. 2018;24(3):372–4. https://doi.org/10.4103/IJPC.IJPC_30_18.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Lewis K, O’Day CS. Dystonic reactions. In: StatPearls (nternet). Updated3/23/ 2019. Treasure Island: StatPearls Publishing. Available at: https://www.ncbi.nlm.nih.gov/books/NBK531466/?report=classic. Accessed 11 Sept 2019.

  25. Caroff SN, Campbell EC. Drug-induced extrapyramidal syndromes: implications for contemporary practice. Psychiatr Clin North Am. 2016;39(3):391–411. https://doi.org/10.1016/j.psc.2016.04.003.

    Article  PubMed  Google Scholar 

  26. Tachere RO, Modirrousta M. Beyond anxiety and agitation: a clinical approach to akathisia. Aust Fam Physician. 2017;46(5):296–8.

    PubMed  Google Scholar 

  27. Poyurovsky M, Weizman A. Treatment of antipsychotic-related akathisia revisited. The role of serotonin 2A receptor antagonists. J Clin Psychopharmacol. 2015;35(6):711–4. https://doi.org/10.1097/JCP.0000000000000412.

    Article  CAS  PubMed  Google Scholar 

  28. Vella-Brincat J, Macleod AD. Haloperidol in palliative care. Palliat Med. 2004;18:195–201. https://doi.org/10.1191/0269216304pm881oa.

    Article  PubMed  Google Scholar 

  29. Prommer E. Role of haloperidol in palliative medicine: an update. Am J Hosp Palliat Care. 2012;29(4):295–301. https://doi.org/10.1177/1049909111423094.

    Article  PubMed  Google Scholar 

  30. Murray-Brown F, Dorman S. Haloperidol for the treatment of nausea and vomiting in palliative care patients (review). Cochrane Database Syst Rev. 2015;(11). https://doi.org/10.1002/14651858.CD006271.pub3.

  31. Digges M, Hussein A, Wilcock A, et al. Pharmacovigilance in hospice/palliative care: net effect of haloperidol for nausea or vomiting. J Palliat Med. 2018;21(1):37–43. https://doi.org/10.1089/jpm.2017.0159.

    Article  PubMed  Google Scholar 

  32. MacKintosh D. Olanzapine in the management of difficult to control nausea and vomiting in a palliative care population: a case series. J Palliat Med. 2016;19(1):87–90. https://doi.org/10.1089/jpm.2015.0224.

    Article  PubMed  Google Scholar 

  33. • Credible Meds. 2019. Available at https://crediblemeds.org/healthcare-providers/. This site, which is frequently updated, lists evidence-based prescription and recreational (cocaine) drugs having the potential to increase the QT interval and induce Torsades de pointes.

  34. Crotti L, Celano G, Dagradi F, Schwartz PJ. Congenital long QT syndrome. Orphanet J Rare Dis. 2008;3:18. https://doi.org/10.1186/1750-1172-3-18.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Kast RE, Foley KF. Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects. Eur J Cancer Care. 2007l;16(4):351–4. https://doi.org/10.1111/j.1365-2354.2006.00760.x.

    Article  CAS  Google Scholar 

  36. Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996;14(2):87–96. https://doi.org/10.1016/0893-133X(94)00129-N.

    Article  CAS  PubMed  Google Scholar 

  37. Passik SD, Lundberg J, Kirsh KL. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manag. 2002;23(6):526–32. https://doi.org/10.1016/S0885-3924(02)00391.

    Article  CAS  Google Scholar 

  38. Kaneishi K, Kawabata M, Morita T. Olanzapine for the relief of nausea in patients with advanced cancer and incomplete bowel obstruction. J Pain Symptom Manag. 2012;44(4):604–7. https://doi.org/10.1016/j.jpainsymman.2011.10.023.

    Article  CAS  Google Scholar 

  39. Raji MA. Management of chemotherapy-induced side-effects. Lancet Oncol. 2005;6(6):357. https://doi.org/10.1016/S1470-2045(05)70182-0.

    Article  PubMed  Google Scholar 

  40. Allen ND, Leung JG, Betcher HK, Borreggine KL, Hosker DK, Minton BA, et al. Mirtazapine for symptomatic relief on a psychiatric consultation service: a case series. Psychosomatics. 2016;57(4):409–13. https://doi.org/10.1016/j.psym.2016.02.012.

    Article  PubMed  Google Scholar 

  41. Anttila SAK, Leinonen EVJ. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001;7(3):249–64. https://doi.org/10.1111/j.1527-3458.2001.tb00198.x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Malamood M, Roberts A, Kataria R, Parkman HP, Schey R. Mirtazapine for symptom control in refractory gastroparesis. Drug Des Devel Ther. 2017;11:1035–41. https://doi.org/10.2147/DDDT.S125743.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Kumar N, Barai S, Gambhir S, Rastogi N. Effect of mirtazapine on gastric emptying in patients with cancer-associated anorexia. Indian J Palliat Care. 2017;23(3):335–7. https://doi.org/10.4103/IJPC.IJPC_17_17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Jaward LR, O’Neil TA, Marks A, Smith MA. Differences adverse effect profiles of corticosteroids in palliative care patients. Am J Hosp Palliat Med. 2019;36(2):158–68. https://doi.org/10.1177/1049909118797283.

    Article  Google Scholar 

  45. Vayne-Bossert P, Haywood A, Good P, et al. Corticosteroids for adult patients with advanced cancer who have nausea and vomiting (not related to chemotherapy, radiotherapy, or surgery). Cochrane Database Syst Rev. 2017;(7). https://doi.org/10.1002/14651858.CD012002.pub2.

  46. Hatano Y, Matsuoka H, Lam L, Currow DC. Side effects of corticosteroids in patients with advanced cancer: a systematic review. Support Care Cancer. 2018;26:3979–83. https://doi.org/10.1007/s00520-018-4339-2.

    Article  PubMed  Google Scholar 

  47. Dietz I, Schmitz A, Lampey I, Schulz C. Evidence for the use of levomepromazine for symptom control in the palliative care setting: a systematic review. BMC Palliat Care. 2013;12:2. https://doi.org/10.1186/1472-684X-12-2.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Laduron PM, Leysen JE. Domperidone, a specific in vitro dopamine antagonist, devoid of in vivo central dopaminergic activity. Biochem Pharmacol. 1979;28:2161–5. https://doi.org/10.1016/0006-2952(79)90198-9.

    Article  CAS  PubMed  Google Scholar 

  49. Barone JA. Domperidone: a peripherally acting dopamine2-receptor antagonist. Ann Pharmacother. 1999;33(4):429–40.

    Article  CAS  Google Scholar 

  50. Bor S, Demir M, Ozdemi O, Yuksel K. A meta-analysis on the cardiac safety profile of domperidone compared to metoclopramide. United European Gastroenterol J. 2018v;6(9):1331–46. https://doi.org/10.1177/2050640618799153.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Field J, Wasilewski M, Bhuta R, et al. Effect of chronic domperidone use on QT interval: a large single center study. J Clin Gastroenterol. 2019. https://doi.org/10.1097/MCG.0000000000001183.

    Article  CAS  Google Scholar 

  52. Ortiz A, Cooper CJ, Alvarez A, Gomez Y, Sarosiek I, McCallum R. Cardiovascular safety profile and clinical experience with high-dose domperidone therapy for nausea and vomiting. Am J Med Sci. 2015;349:421–4. https://doi.org/10.1097/MAJ.0000000000000439.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Gonzalez-Rosales F, Walsh D. Intractable nausea and vomiting due to gastrointestinal mucosal metastases relieved by tetrahydrocannabinol (dronabinol). J Pain Symptom Manag. 1997;14(5):311–4. https://doi.org/10.1016/S0885-3924(97)00229-7.

    Article  CAS  Google Scholar 

  54. Zutt M, Hänßle H, Emmert S, et al. Dronabinol zur supportiven Therapie metastasierter maligner Melanome mit Lebermetastasen (Dronabinol for supportive therapy in patients with malignant melanoma and liver metastases). Hautarzt. 2006;57(5):423–7. https://doi.org/10.1007/s00105-005-1063.

    Article  CAS  PubMed  Google Scholar 

  55. Hernandez SL, Sheyner I, Stover KT, Stewart JT. Dronabinol treatment of refractory nausea and vomiting related to peritoneal carcinomatosis. Am J Hosp Palliat Care. 2015;32(1):5–7. https://doi.org/10.1177/1049909113504240.

    Article  PubMed  Google Scholar 

  56. Di Marzo V. A brief history of cannabinoid and endocannabinoid pharmacology as inspired by the work of British scientists. Trends Pharmacol Sci. 2006;27(3):134–40. https://doi.org/10.1016/j.tips.2006.01.010.

    Article  CAS  PubMed  Google Scholar 

  57. Lu Y, Anderson HD. Cannabinoid signaling in health and disease. Can J Physiol Pharmacol. 2017;95:311–27. https://doi.org/10.1139/cjpp-2016-0346.

    Article  CAS  PubMed  Google Scholar 

  58. •• National Academies of Sciences, Engineering, and Medicine. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. Washington, DC: The National Academies Press; 2017. https://doi.org/10.17226/24625. A comprehensive, in-depth review of existing evidence and summary recommendations regarding health effects of cannabis and cannabis-derived products, as well as potential therapeutic uses. This work was implemented to help advance research and inform public health decisions.

    Book  Google Scholar 

  59. • Schleider LB-L, Mechoulam R, Lederman V, et al. Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer. Eur J Intern Med. 2018;49:37–43. https://doi.org/10.1016/j.ejim.2018.01.023. Analysis of routinely collected data regarding the benefits and burdens of medical marijuana, prescribed to almost 3000 cancer patients with symptomatic disease who were followed over 2 years. This article also describes the processes of physician prescription and nurse selection (with patient) of particular cannabis strains, dose escalation, and patient and family teaching.

    Article  Google Scholar 

  60. Abrams DI. Integrating cannabis into clinical cancer care. Curr Oncol. 2016;23(2):S8–S14. https://doi.org/10.3747/co.23.3099.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adjunct Faculty, Rush University College of Nursing, Chicago, IL, USA

    Rita J. Wickham

Authors
  1. Rita J. Wickham
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rita J. Wickham.

Ethics declarations

Conflict of Interest

Rita J. Wickham has received compensation from Helsinn Healthcare SA and Insys Therapeutics for service as a consultant.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Palliative Medicine

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wickham, R.J. Nausea and Vomiting: a Palliative Care Imperative. Curr Oncol Rep 22, 1 (2020). https://doi.org/10.1007/s11912-020-0871-6

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11912-020-0871-6

Keywords

Search

Navigation